Global Systemic Aspergillosis And Systemic Candidiasis Market Report 2024: Market Size, CAGR, Lucrative Segments And Top Regions

Systemic aspergillosis is the most lethal type of aspergillosis, which develops when the infection spreads to other organs besides the lungs, and systemic candidiasis refers to a range of yeast infections brought on by different species of Candida. Systemic aspergillosis and systemic candidiasis are severe illnesses that can harm the blood, heart, brain, eyes, bones, or other body organs.

Sizing and Forecast
The systemic aspergillosis and systemic candidiasis market size has grown strongly in recent years. It will grow from $6.82 billion in 2023 to $7.2 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%.  The  growth in the historic period can be attributed to increasing incidence of fungal infections, immunocompromised patient population, improved diagnostic technologies, rise in invasive medical procedures, global spread of infections.

The systemic aspergillosis and systemic candidiasis market size is expected to see steady growth in the next few years. It will grow to $8.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%.  The growth in the forecast period can be attributed to global antifungal resistance surveillance, aging population, telemedicine for remote consultations, patient-centric drug development, digital health solutions for patient management. Major trends in the forecast period include new fungal biomarkers for early detection, emergence of novel antifungal agents, advancements in immunotherapy, innovative drug delivery systems.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Segmentation & Regional Insights
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East,  Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

Major Driver Impacting Market Growth
The increase in the incidence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases refer to infections caused by fungi that can affect various body parts, resulting in multiple symptoms and complications. These diseases include cutaneous skin infections, respiratory infections, and systemic infections. Fungal diseases are treated with antifungal medications such as oral azoles, voriconazole, and liposomal amphotericin B. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, the clinical cases of Candida auris, an emerging fungus, increased from 476 in 2019 to 1,471 in 2021. Screening cases increased threefold from 2020 to 2021, to 4,041. Therefore, the increase in the incidence of fungal disease is driving the growth of the systemic aspergillosis and systemic candidiasis market.

Key Industry Players
Major companies operating in the systemic aspergillosis and systemic candidiasis market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

The systemic aspergillosis and systemic candidiasis market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model